Eupraxia Pharmaceuticals Files October 2024 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Nov 1, 2024 · CIK: 1581178
Sentiment: neutral
Topics: filing, regulatory-update
TL;DR
Eupraxia Pharma dropped its Oct 2024 6-K, including a press release from 10/31.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 31, 2024, reporting for the month of October 2024. The filing includes Exhibit 99.1, a press release dated October 31, 2024. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' activities and disclosures for the month of October 2024, which is important for investors to stay informed about the company's ongoing operations and any material information released.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- October 31, 2024 (date) — Press Release Date
- October 2024 (date) — Reporting Period
- Bruce Cousins (person) — Signatory for the filing
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the issuer makes public in its home country or distributes to its security holders.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated October 31, 2024, is included as part of this report.
What is Eupraxia Pharmaceuticals Inc.'s principal executive office address?
The principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Which form does Eupraxia Pharmaceuticals Inc. indicate it will file annual reports under cover of?
Eupraxia Pharmaceuticals Inc. indicates it will file annual reports under cover of Form 40-F.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-10-31 19:39:55
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 19KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001305.txt ( ) — 64KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: October 31, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer